A5113560614- Lipoproteins and Cardiovascular Health
- Blood Pressure and Hypertension Studies
- Hormonal Regulation and Hypertension
- Pharmaceutical Economics and Policy
- Cardiac Imaging and Diagnostics
- Heart Rate Variability and Autonomic Control
- Cardiovascular Function and Risk Factors
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac electrophysiology and arrhythmias
- Cardiac Arrhythmias and Treatments
- Pharmaceutical Practices and Patient Outcomes
- Global Health Workforce Issues
- Pharmacology and Obesity Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Heart Failure Treatment and Management
- Pharmacological Effects and Assays
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Analytical Methods in Pharmaceuticals
- Cardiovascular Syncope and Autonomic Disorders
- Nitric Oxide and Endothelin Effects
- Eicosanoids and Hypertension Pharmacology
- Diversity and Career in Medicine
- Receptor Mechanisms and Signaling
- Coronary Interventions and Diagnostics
- Diabetes Treatment and Management
Johns Hopkins University
2010-2025
Johns Hopkins Medicine
2025
Maryland Dermatology Laser Skin and Vein Institute
2024
Regeneron (United States)
2014-2022
Frankston Hospital
2021
Rutgers New Jersey Medical School
2020
Rutgers, The State University of New Jersey
2014-2020
University of New Haven
2019
Methodist Hospital
2017
Cornell University
2017
Context. Blood pressure control (<140/90 mm Hg) rates for hypertension fall far short of the US national goal 50% or more. Achievable in varied practice settings and geographic regions factors that predict improved blood are not well identified. Objective. To determine success predictors a large trial involving multiethnic population diverse settings. Design. The Antihypertensive Lipid‐Lowering Treatment to Prevent Heart Attack Trial is randomized, double‐blind, active‐controlled clinical...
Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels this enzyme are associated with an increased risk coronary events. Darapladib is a selective oral inhibitor A2.In double-blind trial, we randomly assigned 15,828 patients stable heart disease to receive either once-daily darapladib (at dose 160 mg) or placebo. The primary end point was composite cardiovascular death, myocardial infarction,...
In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy.To evaluate the efficacy and tolerability of evolocumab when used combination with moderate- vs high-intensity statin.Phase 3, 12-week, randomized, double-blind, placebo- ezetimibe-controlled study conducted between January December 2013 primary hypercholesterolemia mixed dyslipidemia at 198 sites 17 countries.Patients (n = 2067) were randomized 1 24 treatment...
We performed a randomized trial comparing intracoronary administration of streptokinase versus dextrose placebo within six hours after the onset symptoms acute myocardial infarction in 40 patients. The base-line clinical, hemodynamic, and angiographic findings were similar control streptokinase-treated groups. Reestablishment flow occurred 12 20 patients treated with 2 given (P less than 0.05). Left ventricular function, ejection fraction, regional wall motion, measured before immediately...
Eplerenone, a selective aldosterone blocker (SAB) that is highly specific for the receptor, has potential to be efficacious in treatment of hypertension. This 8-week, multicenter, double-blind, placebo-controlled trial assessed efficacy, safety, and tolerability eplerenone eligible patients randomized 50, 100, or 400 mg once daily; 25, 200 twice spironolactone 50 placebo. The primary efficacy variable was adjusted mean change baseline final visit seated diastolic blood pressure (DBP). Of 417...
Despite current standard of care, many patients at high risk cardiovascular disease (CVD) still have elevated low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is a fully human monoclonal antibody inhibitor proprotein convertase subtilisin/kexin type 9. The objective the study was to compare LDL-C-lowering efficacy adding alirocumab vs other common lipid-lowering strategies. Patients (n = 355) with very CVD and LDL-C levels 70 mg/dL or greater 100 on baseline atorvastatin 20 40...
Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9 (PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However, the ability detect potentially beneficial changes in other lipoproteins such as (a), triglycerides, high-density (HDL-C), and apolipoprotein (Apo) A1, adverse events (AEs) was limited by sample sizes of individual trials. We report a pooled analysis from four phase 2 studies evolocumab (AMG 145), antibody PCSK9.The...
Background CSL 112 is a new formulation of human apolipoprotein A‐I (apoA‐I) being developed to reduce cardiovascular events following acute coronary syndrome. This phase 2a, randomized, double‐blind, multicenter, dose‐ranging trial represents the first clinical investigation assess safety and pharmacokinetics/pharmacodynamics infusion among patients with stable atherosclerotic disease. Methods Results Patients were randomized single ascending doses (1.7, 3.4, or 6.8 g) placebo, administered...
PURPOSE To determine psychologic outcome, with the focus on emotional or mood state, of young adult survivors childhood acute lymphoblastic leukemia (ALL) compared sibling controls and to identify vulnerable subgroups at highest risk for negative mood. PATIENTS AND METHODS Adult (n = 580), aged > 18 years, who were treated before age 20 years Children's Cancer Group (CCG) protocols ALL 396 administered a structured telephone interview Profile Moods State (POMS), standardized measure...
ABSTRACT. The observation of plasma vasopressin elevations in rats which had been held manually for 1–2 min before decapitation prompted a study this and other stressful stimuli. Plasma concentrations determined by RIA [picograms per ml (±SEM)] were: 1) immediate after removal from cage, 1.69 ± 0.28; 2) manual restraint 3 min, 42.4 12.3; 3) light ether anesthesia, 1.97 0.32; 4) forced exercise the activity wheel (3 min), 2.09 5) swimming 2.2 0.44; 6) noise continuous hammering on cages 1.64...
In this phase 2, randomized, double-blind, placebo-controlled forced dose-titration study, 115 patients with resistant hypertension, receiving background therapy >/=3 antihypertensive medications including a diuretic at full doses, were randomized 2:1 to increasing doses of darusentan (10, 50, 100, 150, and 300 mg), selective endothelin receptor antagonist, or matching placebo once daily for 10 weeks. Darusentan treatment decreased mean systolic diastolic blood pressure levels in...
Blood pressure (BP) control rates and number of antihypertensive medications were compared (average follow‐up, 4.9 years) by randomized groups: chlorthalidone, 12.5–25 mg/d (n=15,255), amlodipine 2.5–10 (n=9048), or lisinopril 10–40 (n=9054) in a double‐blind hypertension trial. Participants hypertensives aged 55 older with additional cardiovascular risk factor(s), recruited from 623 centers. Additional agents other classes added as needed to achieve BP control. was reduced 145/83 mm Hg (27%...
Background We evaluated lipoprotein‐associated phospholipase A 2 (Lp‐ PLA ) activity in patients with stable coronary heart disease before and during treatment darapladib, a selective Lp‐ inhibitor, relation to outcomes the effects of darapladib STABILITY trial. Methods Results Plasma was determined at baseline (n=14 500); 1 month (n=13 709); serially (n=100) 3, 6, 18 months; end treatment. Adjusted Cox regression models associations between levels outcomes. At baseline, median level 172.4...